
|Articles|August 10, 2009
OmniComm Systems To Provide eClinical Solutions for two Phase I HIV Studies
Advertisement
OmniComm Systems (Ft. Lauderdale, FL) announced that it has been selected by an unnamed biopharmaceutical company to provide eClinical solutions for two of its Phase I HIV studies involving over 100 patients. Both HIV studies are expected to run for seven months. The company has already used OmniComm Systems in different therapeutic areas.
OmniComm recently announced acquisitions of EDC assets of ERT and Logos Technologies.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers
2
Is Artificial Intelligence Coming for Clinical Research?
3
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
4
ACT Brief: AI in Clinical Research, FDA Gene Therapy Approval, and High-Performing Hospital Partnerships
5






.png)



.png)



.png)
.png)
